Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – HC Wainwright decreased their Q3 2026 earnings estimates for Merus Labs International in a report issued on Monday, August 17th. HC Wainwright analyst A. He now anticipates that the specialty pharmaceutical company will post earnings per share of ($0.60) for the quarter, down from their prior forecast of ($0.49). HC Wainwright also issued estimates for Merus Labs International’s Q4 2026 earnings at ($0.56) EPS, FY2026 earnings at ($2.69) EPS, Q1 2027 earnings at ($0.60) EPS, Q2 2027 earnings at ($0.66) EPS, Q3 2027 earnings at ($0.69) EPS, Q4 2027 earnings at ($0.71) EPS, FY2027 earnings at ($2.65) EPS, FY2028 earnings at ($2.63) EPS, FY2029 earnings at ($1.23) EPS and FY2030 earnings at $1.20 EPS.
MSL has been the subject of several other reports. Guggenheim raised Merus Labs International to a “strong-buy” rating in a report on Tuesday, April 28th. Canaccord Genuity Group upgraded Merus Labs International to a “moderate buy” rating in a research note on Thursday, May 21st. Three research analysts have rated the stock with a Strong Buy rating and one has given a Buy rating to the stock. According to MarketBeat, Merus Labs International presently has an average rating of “Strong Buy”.
Merus Labs International Price Performance
Merus Labs International has a 52-week low of C$0.95 and a 52-week high of C$1.76.
Merus Labs International Company Profile
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.
Recommended Stories
- Five stocks we like better than Merus Labs International
- Speed Sells: Cerebras Cracks the Silicon Ceiling
- Amid Legal Risks, This Company Is Still Rated a Buy
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
